Videos

LATEST VIDEOS

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

PRESENTED BY
Dr. Tony Sanchez and Josh Wemmer from Invivoscribe, Inc.

March 20th, 2024|

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

PRESENTED BY
Dr. Bevan Tandon, Chief Medical Officer of siParadigm Diagnostics Informatics and Dr. Jason Willis, Lead Hematopathologist of LabPMM (a wholly-owned subsidiary of Invivoscribe) at the AMP 2023 Annual Meeting & Expo

November 16th, 2023|

Watch video

MRD Applications and Analysis

PRESENTED BY
Dr. Linda Lee from Royal North Shore Hospital and Dr. Irene Della Starza from Fondazione GIMEMA Franco Mandelli Onlus and Sapienza University, Rome

()

June 20th, 2023|

Watch video

NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers

PRESENTED BY
Kseniya Petrova-Drus M.D., PhD from Memorial Sloan Kettering Cancer Center

May 31st, 2023|

Watch video

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

PRESENTED BY
Joseph Annunziata, M.D. from Kindred Healthcare

February 28th, 2023|

Watch video

Previous 123 Next

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Videos

Videos

LATEST VIDEOS

Global Search

SEARCH BY KEYWORD

Global Search

SEARCH BY KEYWORD

Looking for Product Documents?
Try our New Document Search Feature ⟶

Looking for Product Documents?
Try our New Document Search Feature ⟶

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

Videos

Videos

LATEST VIDEOS

Level Up Your MRD Testing: Leveraging Standardized & Sensitive AML Assessments

The Evolving Role of NGS and Measurable Residual Disease in CLL/SLL and AML

MRD Applications and Analysis

NGS Assessment of SHM in CLL/SLL: A Practical Comparison of Platforms and Primers

Multiparameter Approach to CLL Diagnosis, Prognostic Biomarker Assessment, and MRD Monitoring

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.